Vertex Pharmaceuticals Inc. said it has entered into deals with GlaxoSmithKline and Janssen Pharmaceuticals to work on potential treatments for hepatitis C. Cambridge-based Vertex already has a hepatitis C drug on the market called Incivek. The separate studies with the British drug company and Janssen, unit of Johnson & Johnson, call for VX-135, another Vertex hepatitis C drug candidate, to be tested in combinations with pills made by those firms. Those studies are scheduled to start early next year.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help